17/12/2025
🚨 Breaking News in Women's Sexual Health 🚨
The FDA has just approved Addyi® (flibanserin) for postmenopausal women, making it the first FDA-approved medication for low sexual desire (HSDD) in both pre- and postmenopausal patients under 65.
This is a historic moment.
For years, millions of women with persistent, distressing low libido have had few evidence-based options. This approval closes a major gap in care and acknowledges what women have been saying all along: sexual health matters at every stage of life.
Addyi is not Vi**ra. It’s a non-hormonal, daily medication that works on brain chemistry to improve sexual desire, reduce distress, and improve quality of sexual experiences
It's supported by the largest clinical trials in women’s sexual health and over a decade of safety data.
This is progress. And it’s long overdue.
